Abstract 371P
Background
Studies showed an increased prevalence of diabetes in pts with PC, and concurrent diabetes is linked with an increased risk of death in many cancers. However, although we know that diabetes is a risk factor for the development of PC, its role as a prognostic factor is unclear. We aimed to investigate the relationship between diabetes and overall survival (OS) in a real-life cohort.
Methods
We retrospectively collected data of consecutive pts from a maintained dataset between 2015 and 2023. OS was calculated from diagnosis, and Kaplan-Meier curves were generated to compare survival rates between diabetic and non-diabetic pts. A log-rank test was performed to determine if there was a significant difference in survival between groups. The Cox regression model was performed to assess the impact of diabetes on OS.
Results
578 pts were included. 123 pts (21%) had diabetes at diagnosis: 38 (31%) pts had metastatic disease, 25 (20%) locally advanced, 20 (16%) borderline resectable, and 40 (33%) resectable disease. In the non-diabetic cohort, 187 pts (41%) had metastatic disease, 100 (22%) locally advanced, 48 (11%) borderline resectable, and 119 (26%) resectable disease. Median age at diagnosis was 68 years (IQR, 62–74) vs 65 years (IQR, 58–73) in the diabetic and non-diabetic cohorts. Median CA 19-9 levels (IU/mL) at diagnosis were 417 (IQR, 78– 050) in the group with diabetes vs 1930 (IQR, 90–1960) in pts without diabetes. There was no significant difference in survival between diabetic and non-diabetic pts (median OS 24.5 vs 17.6 months; HR 1.005; 95% CI, 0.81-1.24; p=0.96), suggesting that patients with diabetes had no higher risk of death compared to those without diabetes.
Conclusions
Even though there was a remarkable difference in CA 19-9 levels between diabetic and non-diabetic pts, diabetes did not impact the survival of pts with PC in our population. In addition, the distribution of different disease stages at diagnosis was similar, potentially excluding an impact on the survival analysis. Considering the limiting confounding factors related to single-center accrual and retrospective analysis, the role of diabetes should be further investigated in large prospective studies.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Balsano: Financial Interests, Personal, Other, Lecture Fees: AstraZeneca; Financial Interests, Personal, Other, Travel Expenses: Roche. T. Pressiani: Financial Interests, Personal, Other, Consulting fees: Bayer, Ipsen, AstraZeneca; Financial Interests, Personal, Other, Institutional research funding: Roche, Bayer, AstraZeneca; Financial Interests, Personal, Other, Travel expenses: Roche. L. Rimassa: Financial Interests, Personal, Other, Consulting fees: AbbVie, AstraZeneca, Basilea, Bayer, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier; Financial Interests, Personal, Other, Travel expenses: AstraZeneca; Financial Interests, Personal, Other, Institutional research funding: Agios, AstraZeneca, BeiGene, Eisai, FibroGen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, Zymeworks. All other authors have declared no conflicts of interest.